Latest Aethlon Medical News & Updates

See the latest news and media coverage for Aethlon Medical. We track all announcements, press releases, and industry mentions in real time, all in one place.

Aethlon Medical

Medical device developer for cancer and viral infections

aethlonmedical.com

Headquarters: San Diego, United States
Founded year: 1999
Company type: Public company
Number of employees: 24–50
Industry: Biotechnology & Medical Research

Last updated October 9

Latest news about Aethlon Medical

In short: Aethlon Medical announced a $180 million merger with North Immunology to develop NOR-101

Company announcements

September 17 Aethlon Medical

Aethlon Medical announces merger with North Immunology for $180 million in funding

The combined entity will focus on developing the NOR-101 bispecific antibody for atopic dermatitis and expects to complete the transaction by early 2027.

August 13 Aethlon Medical

Aethlon Medical shares Q1 2027 financial and clinical updates

The company reports $4.9 million in cash, a $4.0 million public stock offering after the quarter, an 11.9% decrease in operating expenses, and Phase 1 oncology trial advancements alongside accepted Long COVID research.

July 6 Aethlon Medical

Aethlon Medical prices a four million dollar follow-on equity offering

The company plans to allocate the net proceeds toward research and development, clinical trials, and working capital. Maxim Group acts as placement agent with closing anticipated shortly.

June 10 Aethlon Medical

Aethlon Medical reports March 2026 fiscal year financial results

The company advanced its Australian oncology trial into the final dosing cohort, secured new patents for Long COVID applications, and reduced operating expenses by nearly twenty-two percent compared to the previous fiscal year.

Media coverage

October 9 The Globe and Mail

Aethlon Medical Expands Authorized Common Stock Capacity

Detailed price information for Aethlon Medical Inc (AEMD-Q) from The Globe and Mail including charting and trades.

September 16 Barron's

Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis

North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both type 2 and non-type 2 inflammation, with...

September 16 Northwest Arkansas Home Page

SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aethlon Medical, Inc. (NASDAQ: AEMD)

The firm is headquartered at the Empire State Building in New York City and is investigating Aethlon...

August 13 RTTNews

Aethlon Posts Narrower Q1 Loss, Stock Jumps

For the first quarter, loss attributable to common stockholders marginally narrowed by 12% to $1.55 million from $1.76 million in the prior-year. On a per...

Never miss news about Aethlon Medical

Track Aethlon Medical and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.